GMP-Creative Biolabs provides one-stop customer-oriented services including biopharmaceutical contract R&D, process development, cGMP manufacturing, QA & QC solutions for scientific research, preclinical, clinical and commercial supply. We proceed your projects according to your specific demands in quality, timeline and budget, supporting researchers across different therapeutic areas. Clear, open and regular communication with customers is as important to our success as our in-depth scientific knowledge. more
Creative Biolabs provides Saccharomyces cerevisiae (S. cerevisiae) as host cells to produce recombinant proteins. Other than E. coli system, the yeast systems, such as S. cerevisiae and P. pastoris, constitute another microbial systems in heterologous protein expression. S.cerevisiae is the first yeast system used to produce recombinant proteins.
Yeast hosts can be classified into two categories: non-methylotrophic yeasts and methylotrophic yeasts. Many of non-methylotrophic yeasts, lacking endotoxins and lytic viruses, are well-known for the established applications for the production of enzymes, vitamins, etc. S. cerevisiae is a member of non-methylotrophic yeasts. It has the advantages of bacterial systems to grow fast and can also perform post-translational modifications and secretion to drop the cost of post-fermentation in vitro purification and modification. Moreover, it possesses the ability to be tolerant to special conditions such as low pH, high osmotic pressure, high sugar and ethanol concentrations, which makes it suitable for industrial fermentations. Advanced fermentation techniques (continuous and fed-batch processes) and technologies (computer-controlled fermentations) are also available. And during the industrial processes, there is a wide range of carbon and energy sources that can be used. It has a long history to use S. cerevisiae for commercial production of therapeutic proteins including hormones (e.g. insulins, human growth hormones) and virus-like particles (e.g. the major capsid protein L1 of some human papillomavirus types). Up to 2009, there are 28 human therapeutic and prophylactic proteins produced in S.cerevisiae that have been approved. During cell line development, there are two approaches for the heterologous gene to be introduced into host cells: integrative plasmid; autonomous or episomal circular plasmids. And the transformants can be selected by complementation of autotrophic markers, by dominant markers or by the so-called auto-selection systems. In S. cerevisiae system, the LEU2 gene (auxotrophic markers) and the G418 resistance gene (dominant markers) are the most popular used markers. Finally, the heterologous proteins expressed is targeted to the cytoplasm or selected. Cytoplasmic expression receives high expression levels but often needs additional process steps during the downstream processing of the products. Alternatively, proteins can be secreted by adding an appropriate secretion signal sequence. The S. cerevisiae α mating factor (α-MF) signal is the most used signal sequence. By using α-MF signal, high secretion levels have been achieved in S. cerevisiae, K. lactis, Z. bailii, P. pastoris and H. polymorpha.
Based on the products type and the specific requirements of every client, scientists from Creative Biolabs will design and select the most appropriate vector systems to develop stable cell lines of S. cerevisiae.
Creative Biolabs provides the following microbial systems for various proteins expression:
To discuss your Saccharomyces cerevisiae (S. cerevisiae) Cell Lines demands or to request a proposal, please contact us by
For R&D use only, not directly for clinical use.